This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT01963598 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Regeneron Pharmaceuticals |
| Enrollment | 253 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Sarcopenia |
| Interventions | REGN1033 (SAR391786); placebo |
| Start | Nov 2013 |
| Primary completion | Jan 2015 |
| Study completion | Feb 2015 |
| Results posted | Not yet |
| Registry last updated | Mar 28, 2016 |
| Collaborators | Sanofi |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in patients with sarcopenia.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent change in total lean body mass | day 1 to day 85 |
10 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 30, 2026. See the trial changes feed for what has changed recently.
More trials of Trevogrumab
Research area: Related non-peptide compounds. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
